4.5 Article

Characterisation of COPD heterogeneity in the ECLIPSE cohort

Journal

RESPIRATORY RESEARCH
Volume 11, Issue -, Pages -

Publisher

BMC
DOI: 10.1186/1465-9921-11-122

Keywords

-

Funding

  1. GlaxoSmithKline
  2. Almirall
  3. AstraZeneca
  4. Boheringer-Ingelheim
  5. Roche
  6. Nycomed
  7. Novartis and Procter Gamble
  8. Nycomed and Pfizer
  9. GlaxoSmithKline and Nycomed
  10. Boehringer-Ingelheim and GlaxoSmithKline
  11. Boehringer-Ingelheim
  12. Forrest Medical
  13. Astra Zeneca and Aeris
  14. Aeris and Deep Breeze
  15. Almirall and Esteve
  16. AstraZeneca (Australia)
  17. Boehringer-Ingelheim, Pfizer
  18. ECLIPSE
  19. Medical Research Council [G9900991B, G0500306] Funding Source: researchfish
  20. MRC [G0500306] Funding Source: UKRI

Ask authors/readers for more resources

Background: Chronic obstructive pulmonary disease (COPD) is a complex condition with pulmonary and extra-pulmonary manifestations. This study describes the heterogeneity of COPD in a large and well characterised and controlled COPD cohort (ECLIPSE). Methods: We studied 2164 clinically stable COPD patients, 337 smokers with normal lung function and 245 never smokers. In these individuals, we measured clinical parameters, nutritional status, spirometry, exercise tolerance, and amount of emphysema by computed tomography. Results: COPD patients were slightly older than controls and had more pack years of smoking than smokers with normal lung function. Co-morbidities were more prevalent in COPD patients than in controls, and occurred to the same extent irrespective of the GOLD stage. The severity of airflow limitation in COPD patients was poorly related to the degree of breathlessness, health status, presence of co-morbidity, exercise capacity and number of exacerbations reported in the year before the study. The distribution of these variables within each GOLD stage was wide. Even in subjects with severe airflow obstruction, a substantial proportion did not report symptoms, exacerbations or exercise limitation. The amount of emphysema increased with GOLD severity. The prevalence of bronchiectasis was low (4%) but also increased with GOLD stage. Some gender differences were also identified. Conclusions: The clinical manifestations of COPD are highly variable and the degree of airflow limitation does not capture the heterogeneity of the disease.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available